

## Expanding the Clinical Features of Schimke Immuno-Osseous Dysplasia: A New Patient with a Novel Variant and Novel Clinical Findings

### Alavanda C et al. Novel Pathogenic Variant in *SMARCAL1* Gene Detected in SIOD Patient

Ceren Alavanda<sup>1,2</sup>, Şenol Demir<sup>2</sup>, Serçin Güven<sup>3</sup>, Mehmet Eltan<sup>4</sup>, Sevgi Bilgiç Eltan<sup>5</sup>, Asena Pınar Sefer<sup>5</sup>, Serim Pul<sup>3</sup>, Tülay Güran<sup>4</sup>, Harika Alpay<sup>3</sup>, Ahmet Arman<sup>2</sup>, Pınar Ata<sup>2</sup>, Serap Turan<sup>4</sup>

<sup>1</sup>Department of Medical Genetics, Van Research and Training Hospital, Van, Türkiye

<sup>2</sup>Department of Medical Genetics, School of Medicine, Marmara University, Istanbul, Türkiye

<sup>3</sup>Department of Pediatric Nephrology, School of Medicine, Marmara University, Istanbul, Türkiye

<sup>4</sup>Department of Pediatric Endocrinology, School of Medicine, Marmara University, Istanbul, Türkiye

<sup>5</sup>Department of Pediatric Allergy and Immunology, School of Medicine, Marmara University, Istanbul, Türkiye

#### Abstract

Schimke Immuno-Osseous Dysplasia (SIOD) (MIM:242900) is an ultra-rare autosomal recessive pan-ethnic pleiotropic disease. Typical findings of this syndrome are steroid-resistant nephrotic syndrome, cellular immunodeficiency and spondyloepiphyseal dysplasia and facial dysmorphism. Biallelic variants in the *SMARCAL1* gene cause SIOD. The five-and-half-year-old female patient was evaluated because of short stature, dysmorphism, hypercalcemia, hypophosphatemia and elevated FSH levels. Karyotype analysis and array-CGH testing were normal. Clinical Exome Sequencing was performed via next-generation sequencing to analyze genes associated with hypophosphatemia. No pathogenic variant was detected. The subsequent detection of proteinuria during her follow-up for cross-fused ectopic left kidney ultimately facilitated the diagnosis of SIOD, although no obvious spondyloepiphyseal dysplasia was detected. Re-analysis of CES revealed a novel homozygous c.2422\_2427+9delinsA pathogenic variant in the *SMARCAL1*. One hundred twenty-five SIOD cases from 38 literature reporting *SMARCAL1* gene pathogenic variants were reviewed to investigate whether hypercalcemia, hypophosphatemia and elevated FSH levels had been previously reported in SIOD patients. This review revealed that this was the first time these findings had been reported in a SIOD patient. This report expands not only the phenotypic but also genotypic spectrum of SIOD.

**Keywords:** *SMARCAL1*, hypercalcemia, hypophosphatemia, ectopic kidney, gonadal dysfunction

Ceren Alavanda, MD, Department of Medical Genetics, Van Research and Training Hospital, Van, Turkey

+905369745018

[cerenalavanda@gmail.com](mailto:cerenalavanda@gmail.com)

29.01.2024

25.07.2024

0000-0002-7327-3849

## Introduction

Schimke Immuno-Osseous Dysplasia (SIOD) (MIM:242900) is an ultra-rare autosomal recessive pan-ethnic pleiotropic disease. Prevalence of SIOD disease is 1 in 1-3 million live births in USA (1). This syndrome was first described as chondroitin-6-sulfate mucopolysaccharidosis (2). Then with further studies, mucopolysaccharidosis was excluded (3). Main findings of this syndrome are steroid resistant nephrotic syndrome, immunodeficiency and spondyloepiphyseal dysplasia (SED). The short stature observed in almost all patients is due to SED (4). Renal disease, mostly due to focal segmental glomerulosclerosis (FSGS), is progressive and eventually leads to end-stage renal failure. Defective cellular immunity is the cause of immunodeficiency. Patients also exhibit typical phenotypic features such as fine hair, a triangular face, a depressed nasal bridge, a bulbous nasal tip, microdontia, a short neck, a short trunk, hyperpigmented macules and a protruding abdomen. In 2002, it was discovered that biallelic pathogenic variants in *SMARCA1* gene (*SWI/SNF-related, matrix associated, actin dependent regulator of chromatin, subfamily A-like 1*) cause this syndrome (5).

Here, we present a patient with SIOD who exhibited an atypical clinical presentation characterized by hypercalcemia and hypophosphatemia, resembling osteopenia of prematurity, along with elevated follicle stimulating hormone (FSH) levels indicative of primary gonadal failure. Furthermore, we conducted a review of all genetically confirmed cases of SIOD, providing an occurrence ratio of clinical and laboratory findings in comparison with our patient.

## Case presentation:

One and half year-old female was referred to medical genetics out-patient clinic with disproportionate short stature and renal failure. She was the second child of healthy 33-year-old mother and 36-year-old father. Although there was no consanguinity between her parents, they both came from the same small village. Family history was unremarkable. She was born at 30th gestational week with a birth weight of 945 g (-2.1 SD) and birth length of 35 cm (-2 SD), and was hospitalized at neonatal intensive care unit (NICU) for 3 months due to prematurity. At that time, patent ductus arteriosus, patent foramen ovale, and atrial septal defect were detected at echocardiography. Her cranial ultrasonography (USG) was normal. She passed the hearing test and her ophthalmologic examination revealed no retinopathy of prematurity.

At the initial presentation, at the age of 7 months, she was referred to the pediatric endocrinology clinic for hypercalcemia. On physical examination, height was 58 cm (-3.9 SD) and weight was 4.5 kg (-4.4 SD), and head circumference was 38 cm (-4.2 cm), while mid-parental height was at -1 SD. The dysmorphic examination revealed that she had fine and sparse hair, microcephaly, prominent forehead, synophrisis, upslanting palpebral fissures, malar hypoplasia, depressed nasal bridge, bulbous nasal tip, long philtrum, thin upper lip, retrognathia, everted lower lip, microdontia, posterior rotated and low set ears, anteverted ears, short neck, short trunk, hyperpigmented macules on the trunk, protruding abdomen, tapering fingers, brachydactyly (Figure 2). External genitalia was normal.

The laboratory evaluation revealed the following results: Ca of 11.6 mg/dL (N:8.7-11), PO<sub>4</sub> of 3.2 mg/dL (N:5-7.8), ALP of 1122 U/L (N:116-450), 25-OH vitamin D of 24.4 ug/L (N:30-100), PTH of 6.2 ng/L (N:15-65), Cre:0.19 mg/dL (N:0-0.42), Mg:2.4 mg/dL (N:1.8-2.6), U-Ca/Cre ratio of 0.4 mg/mg (N:0.03-0.8), TRP of 98% (N:85-100) and TmP/GFR of 5.45 (N:4.8-8). The laboratory and wrist X-ray were consistent with the osteopenia of prematurity and rickets, which were related to phosphate deficiency. Phosphate replacement therapy was initiated and continued for 5 months, resulting in the normalization of biochemical parameters and the improvement of radiological findings (Figure 2).

The patient exhibited no catch-up growth with poor growth velocity. She began to sit independently at 10 months old and started walking at 18 months. She had her first words at 18 months.

Endocrinological evaluation of short stature at age of 19 months revealed low levels of IGF-1 (-2 SD) and IGFBP-3 (-2.4 SD) along with elevated FSH level (24 U/L). Biochemical parameters, including renal function and celiac antibodies, showed no abnormality. The bone age was consistent with the chronological age (Figure 2a.3). Turner syndrome was considered as a potential diagnosis due to the presence of short stature, an ectopic kidney and elevated FSH levels. However, karyotype analysis and array-CGH testing demonstrated a 46,XX karyotype with no deletion or duplication. Furthermore, a growth hormone (GH) stimulation test with glucagon showed a high basal GH level (17.6 ng/ml) and an exaggerated peak GH response (32 ng/ml) with consistently elevated GH levels throughout the test. The First TSH elevation was detected at age 3 and 3.5 years-old as 6.44 mIU/L and 12.80 mIU/L (N:0.70-5.97), respectively.

Furthermore, the ultrasound of the urinary tract showed a cross-fused ectopic left kidney at initial evaluation. The patient was referred to pediatric nephrology. At nephrological follow-up of the patient, she experienced recurrent urinary tract infections. She was diagnosed with nephrotic syndrome at the age of 1.5 years. She was treated with albumin infusions, diuretics, ACE inhibitors and corticosteroids but failed to respond. The patient presented a severe decompensation of her nephrotic syndrome that required peritoneal dialyses for 10 months and she received a kidney transplant from her uncle when she was 4 years old. The patient was not deemed to need a renal biopsy since she received a genetic diagnosis. The patient's initial blood pressure measurement was 92/54 mmHg, while in the last measurement, it was 118/84 mmHg (N:105/63).

Nephrological evaluation revealed hemoglobin:15.6 g/dl (N:12-16), hematocrit:46.7% (N:36-48), MCV:80.9 fl (N:80-100), WBC: 7.3x10<sup>3</sup>/μl (N:4.5-11x10<sup>3</sup>), mild lymphopenia (1x10<sup>3</sup>/μl)(N:1-4.8x10<sup>3</sup>), platelets: 293x10<sup>3</sup>/l (N:150-450x10<sup>3</sup>), hypoalbuminemia (albumin 2.2 g/dl(N:3.4-5.4)), high total cholesterol level (382 mg/dl, N:<200)) and hypertriglyceridemia (253 mg/dl (N:<150)). Urinalysis demonstrated 3+ proteinuria. Spot urine protein was 1043 mg/dl (N:0-10), urine creatinine 37 mg/dl (N:20-275), and the urine protein/creatinine ratio were calculated as 28.1 mg/mg creatinine (N:<0.5). Serum complement C3 level (197 mg/dl, N:80-120) and C4 level (59 mg/dl, N:10-40) were within normal limits.

Although no obvious bone dysplasia was initially detected on hand X-rays, SIOD was considered as a potential diagnosis after the development of nephrotic syndrome. However, a more comprehensive skeletal survey revealed certain skeletal abnormalities including ovoid vertebral bodies, shallow acetabular fossae with laterally displaced femoral heads (Figure 2c, d). Notably, there were no epiphyseal changes observed. Subsequent X-rays taken at the age of five-and-half-years displayed mild platyspondyly, metaphyseal widening of the long bones, and osteopenia with metaphyseal sclerosis (Figure 2d.1).

Immunological analyses at the age of 34 months revealed lymphopenia of 1.300/ul, low serum IgG: 157 mg/dl (N:604-1921), normal IgA: 58 mg/dl (N:26-228), and IgM level: 167 mg/dl (N:71-235). Serum IgE level was slightly elevated as 149 IU/ml. The patient had also anemia and thrombocytopenia. Responses to protein antigens, including hepatitis B, mumps IgG were negative and measles, varicella, rubella IgG were positive. Lymphocyte subgroup analysis showed severe CD3+ T, CD4+ T, and CD8+ T lymphopenia accompanied by decreased naive and increased memory CD4+ and CD8+ T cells. Elevated CD19+ B lymphocyte numbers were detected, on the other hand CD16+ CD56+ NK cell numbers were normal. Although the patient had no history of recurrent infections other than recurrent urinary tract infections, concomitant prophylactic antibiotic and immunoglobulin infusions were administered every 3 weeks with the diagnosis of combined immunodeficiency. The clinical findings of the patient are summarized in Table 1.

After obtaining informed written consent from patient's parents, DNA was isolated from the peripheral blood of the patient using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Clinical Exome Sequencing (CES) was performed via next-generation sequencing (Illumina Nextseq 500) using Sophia Clinical Exome Solution V2. Data were analyzed through Sophia DDM-V4 platform. Non-synonymous (missense, nonsense, in-frame, frameshift) variants with minor allele frequency less than 1.0% in population studies (1000 Genomes-1000G, Exome Aggregation Consortium database-ExAC and Genome Aggregation Database-gnomAD) were filtered. American College of Medical Genetics and Genomics (ACMG) criteria were also used. Retained variants were searched in Clinvar and Human Genome Mutation Database (HGMD). Segregation analyses were also performed via Illumina Nextseq 500. Molecular analysis revealed a novel homozygous c.2422\_2427+9delinsA (NM\_001127207) variant in the *SMARCA1* gene (Figure 3a). It was localized at the donor site of 15th exon. This variant was not reported in Clinvar and HGMD. According to ACMG criteria this variant was pathogenic (PVS1, PM2, PP3). Segregation analysis revealed that her parents were heterozygous for this variant (Figure 3b, c). Given the presentation at age of 7 months with hypophosphatemia and required phosphate replacement, genetic causes of hypophosphatemia were considered. No variant was detected in the customized panel containing *PHEX*, *DMP1*, *FGF23*, *ANKH*, *CYP27B1*, *CYP2R1*, *VDR*, *CYP3A4*, *CYP24A1*, *SLC34A1*, *SLC34A3*, *KL*, *GALNT3*, *CLCN5*, *SLC2A2*, *OCRL*, *FAM20C*, *FGFR1*, *ABCC6*, *ALPL*, *EXT1*, *SLC9A3R1*, *AVPR2* genes selected from CES.

#### **Discussion:**

Schimke immuno-osseous dysplasia is a pleiotropic disorder with typical clinical findings: short stature, SED, immune deficiency, renal involvement and typical dysmorphic findings. However, the diagnosis of SIOD can be challenging before occurrence of renal findings as observed in our cases. Our patient was born prematurely with intrauterine growth retardation (IUGR) and required prolonged hospitalization in the NICU. Subsequently, she presented to the clinic with hypercalcemia related to the hypophosphatemia and needed 5 months of phosphate replacement. Genetic analysis for hypophosphatemia revealed no etiology, and she was accepted as having osteopenia of prematurity. Later follow-up demonstrated no catch-up growth and the presence of elevated FSH along with an ectopic kidney suggested Turner syndrome. However, further investigation, including a normal female karyotype and array-CGH testing did not confirm this

diagnosis. Nephrological follow-up for the patient, focusing on cross-fused ectopic left kidney and recurrent urinary tract infections, ultimately led to the early diagnosis of proteinuria and SIOD.

When we analyzed all genetically confirmed cases of SIOD in the literature, all cases exhibited short stature, and almost all (94.4%) had IUGR. Additionally, proteinuria was a consistent feature in all cases, serving as the primary indicator leading to the diagnosis of SIOD, as observed in our case. Although short stature is a universal feature of SIOD, only a few patients have been evaluated for the GH/IGF-1 axis. Almost all of evaluated cases demonstrated normal GH levels in GH stimulation tests (6, 7, 8, 9). Furthermore, when the patients were treated with GH, they responded poorly to GH treatment (4, 5, 10, 11, 12) even in the case of low GH levels at GH stimulation tests (13). Our patient, however, showed high basal GH level and an exaggerated peak GH response to stimulation, along with low IGF-1 and IGFBP-3 levels, indicative of GH resistance. When all reported patients were evaluated from this perspective, although most GH stimulation tests were described as normal (exact values not provided), at least one patient had GH levels similar to ours (8). However, IGF-1 and IGFBP-3 levels were not mentioned in any of the patients. In light of the poor response to GH treatment, normal or high GH levels, and low IGF-1 and IGFBP-3 levels in our case, SIOD can be considered a condition of GH resistance related to the primary disease. Furthermore, the final height of the patient with SIOD ranged from 110 to 165 cm for males and from 107 cm to 143 cm for females (5, 14). Table 1 presents a comprehensive overview of all reported findings in literature along with the details of our case.

Primary gonadal failure and elevated FSH levels had not been previously reported in any SIOD patients. The FSH level was reported only once in a 14-year-old male patient and was found to be normal (8). However, cryptorchidism has been reported in five patients and can be a sign of hypogonadism (12, 15, 16, 17, 18). Furthermore, *SMARCAL1* expression was found in fetal ovaries and testis (19). Therefore, pathogenic variants in this gene may lead to gonadal dysfunction. The reason of the gonadal failure remaining unrecognized in SIOD could be due to the severity of renal or other systemic diseases and renal transplantation. More detailed laboratory studies are required in other cases of SIOD for further explanation of this issue. Unfortunately, although our patient had persistently elevated FSH levels, we did not have any anti-Mullerian hormone measurement done in our case.

The other features we report for the first time here are hypercalcemia, hypophosphatemia and rickets in SIOD. However, these features may not be inherent to SIOD and could be a co-occurrence related to prematurity and insufficient phosphate intake.

Renal phenotype of SIOD is steroid-resistance nephrotic syndrome, which is progressive and often leads to end-stage renal failure. The main renal histopathology is FSGS; however, minimal glomerular lesions and podocytic infolding glomerulopathy can also be detected (20, 21). Our patient exhibited an additional renal phenotype, namely crossed fused ectopic kidney. Our literature review of a total 125 genetically confirmed patients from 40 articles revealed crossed fused ectopic kidney in two SIOD patients (18, 22). Additionally, one patient with an ectopic kidney (23) and another patient with unilateral renal agenesis (24) have been reported. *SMARCAL1* expression is known to be high in fetal kidneys and collecting ducts (22). Therefore, the association between *SMARCAL1* pathogenic variants and renal malformations is an expected finding. As suggested by Dekel et al., this finding may have been overlooked (22). Evaluating SIOD patients for renal malformations will contribute to our understanding of whether renal malformations are incidental findings or a rare component of SIOD.

Furthermore, the clinical presentation or progression of SIOD is classified as severe and mild (4). In severely affected patients, IUGR, neurologic manifestations such as cerebral infarction and transient ischemic attack, hypothyroidism and bone marrow failure are observed more frequently (5). End-stage renal failure can occur at an earlier age in severely affected patients and most die within the first 15 years of life (5). The most common causes of death are severe infections, cerebral ischemia, and renal failure (4). The immune phenotype is predominantly characterized by lymphopenia and T cell failure, leading to recurrent infections, which are one of the most important causes of death (4). The presence of IUGR, early-onset renal failure, elevated TSH levels, and immunodeficiency in our patient, consistent with a severe phenotype, leads us to anticipate that the patient could experience neurological complications by age.

Additionally, the detection of a truncating variant in our patient indicated a severe phenotype. Patients with biallelic non-truncating variants tend to have a milder phenotype, although a strict genotype-phenotype correlation has not been found in SIOD patients. There was no significant difference observed between patients carrying truncating and non-truncating variants, particularly concerning the renal phenotype. However, it has been demonstrated that patients with biallelic truncating mutations exhibit higher mortality rates than those with biallelic missense variants (4). Furthermore, different clinical severities have been observed in two siblings carrying the same variant, indicating intrafamilial variability (10).

The *SMARCAL1* gene contains 18 exons and encodes 954 amino acid protein. *SMARCAL1* protein is highly conserved and belongs to Sucrose Non-Fermenting 2 (SNF2) family (25). It functions as an ATP-dependent chromatin remodeling protein involved in various biological activities such as replication, transcription and DNA damage response. The protein contains four functionally important domains:

HepA-related protein 1 (HARP1, 226-303 amino acids), HARP2 (327-398 amino acids), helicase ATP-binding domain (445-600 amino acids), and helicase C-terminal domain (716-869 amino acids). As of June 25, 2023, the HGMD lists 150 pathogenic variants in the *SMARCAL1* gene, with the majority being truncating variants. SIOD-related variants are depicted in Figure 4 of the database with many pathogenic variants located within two helicase domains, similar to the variant detected in our study.

Herein, we present a patient with SIOD who exhibited an atypical clinical presentation characterized by hypercalcemia and hypophosphatemia, resembling osteopenia of prematurity, along with elevated FSH levels indicating primary gonadal failure. We identified a homozygous novel indel variant in the donor splice-site of the *SMARCAL1* gene. This report expands not only the phenotypic but also the genotypic spectrum of SIOD.

#### **Acknowledgments:**

We would like to thank the patient and her parents for their contributions.

**Statement of Ethics:** Written informed consent was obtained from the patient's parents.

**Conflict of Interest Statement:** The authors have no conflicts of interest to declare. Funding Sources: This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Author Contributions:** Ceren Alavanda, Şenol Demir, Ahmet Arman, Pınar Ata provided genetic evaluation. Serçin Güven, Serim Pul, Harika Alpay provided nephrologic evaluation. Mehmet Eltan, Tülay Güran, Serap Turan provided endocrine evaluation. Sevgi Bilgiç Eltan and Asena Pınar Sefer provided immunologic evaluation. Ceren Alavanda and Serap Turan wrote the manuscript.

**Data Availability Statement:** All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

#### **References**

1. Santangelo L, Gigante M, Netti GS, Diella S, Puteo F, Carbone V, Grandaliano G, Giordano M, Gesualdo L. A novel *SMARCAL1* mutation associated with a mild phenotype of Schimke immuno-osseous dysplasia (SIOD). *BMC Nephrol.* 2014;15:41.
2. Schimke RN, Horton WA, King CR. Chondroitin-6-sulphaturia, defective cellular immunity, and nephrotic syndrome. *Lancet.* 1971;2(7733):1088-9.
3. Spranger J, Hinkel GK, Stöss H, Thoenes W, Wargowski D, Zepp F. Schimke immuno-osseous dysplasia: a newly recognized multisystem disease. *J Pediatr.* 1991;119:64-72.
4. Lipska-Ziętkiewicz BS, Gellermann J, Boyer O, Gribouval O, Ziętkiewicz S, Kari JA, Shalaby MA, Ozaltın F, Dusek J, Melk A, Bayazit AK, Massella L, Hyla-Klekot L, Habbig S, Godron A, Szczepańska M, Bienias B, Drożdż D, Odeh R, Jarmużek W, Zachwieja K, Trautmann A, Antignac C, Schaefer F; PodoNet Consortium. Low renal but high extrarenal phenotype variability in Schimke immuno-osseous dysplasia. *PLoS One.* 2017;12(8):e0180926.
5. Boerkoel CF, O'Neill S, André JL, Benke PJ, Bogdanović R, Bulla M, Burguet A, Cockfield S, Cordeiro I, Ehrich JH, Fründ S, Geary DF, Ieshima A, Illies F, Joseph MW, Kaitila I, Lama G, Leheup B, Ludman MD, McLeod DR, Medeira A, Milford DV, Ormála T, Rener-Primec Z, Santava A, Santos HG, Schmidt B, Smith GC, Spranger J, Zupancic N, Weksberg R. Manifestations and treatment of Schimke immuno-osseous dysplasia: 14 new cases and a review of the literature. *Eur J Pediatr.* 2000;159(1-2):1-7.
6. Yue Z, Xiong S, Sun L, Huang W, Mo Y, Huang L, Jiang X, Chen S, Hu B, Wang Y. Novel compound mutations of *SMARCAL1* associated with severe Schimke immuno-osseous dysplasia in a Chinese patient. *Nephrol Dial Transplant.* 2010;25(5):1697-702.
7. Liu S, Zhang M, Ni M, Zhu P, Xia X. A novel compound heterozygous mutation of the *SMARCAL1* gene leading to mild Schimke immune-osseous dysplasia: a case report. *BMC Pediatr.* 2017;17(1):217.
8. Wang L, Li J, Wu G, Kong X. A novel compound heterozygous variant in *SMARCAL1* leading to mild Schimke immune-osseous dysplasia identified using whole-exome sequencing. *J Int Med Res.* 2021;49(4):3000605211010644.

9. Zieg J, Krepelova A, Baradaran-Heravi A, Levchenko E, Guillén-Navarro E, Balascakova M, Sukova M, Seeman T, Dusek J, Simankova N, Rosik T, Skalova S, Lebl J, Boerkoel CF. Rituximab resistant evans syndrome and autoimmunity in Schimke immuno-osseous dysplasia. *Pediatr Rheumatol Online J*. 2011;9(1):27.
10. Lücke T, Billing H, Sloan EA, Boerkoel CF, Franke D, Zimmering M, Ehrich JH, Das AM. Schimke-immuno-osseous dysplasia: new mutation with weak genotype-phenotype correlation in siblings. *Am J Med Genet A*. 2005;135(2):202-5.
11. Woo HA, Kim SH, Ahn YH, Min SI, Ha J, Ha IS, Cheong HI, Kang HG. Clinical course of post-kidney transplant Schimke immuno-osseous dysplasia. *Pediatr Transplant*. 2023;27(8):e14605. doi: 10.1111/ptr.14605.
12. Barraza-García J, Rivera-Pedroza CI, Belinchón A, Fernández-Cambor C, Valenciano-Fuente B, Lapunzina P, Heath KE. A novel SMARCAL1 missense mutation that affects splicing in a severely affected Schimke immunoosseous dysplasia patient. *Eur J Med Genet*. 2016;59(8):363-6.
13. Belefrod DT, Diab M, Qubty WF, Malloy MJ, Long RK, Shieh JT. Schimke immunoosseous dysplasia and management considerations for vascular risks. *Am J Med Genet A*. 2019;179(7):1246-1252.
14. Lücke T, Franke D, Clewing JM, Boerkoel CF, Ehrich JH, Das AM, Zivicnjak M. Schimke versus non-Schimke chronic kidney disease: an anthropometric approach. *Pediatrics*. 2006;118(2):e400-7. doi: 10.1542/peds.2005-2614.
15. Taha D, Boerkoel CF, Balfe JW, Khalifah M, Sloan EA, Barbar M, Haider A, Kanaan H. Fatal lymphoproliferative disorder in a child with Schimke immuno-osseous dysplasia. *Am J Med Genet A*. 2004;131(2):194-9.
16. Düzova A, Gülhan B, Topaloğlu R, Özaltın F, Cengiz AB, Yetimakman AF, Doğru D, Güçer Ş, Beşbaş N. BK virus associated nephropathy and severe pneumonia in a kidney transplanted adolescent with Schimke immuneosseous- dysplasia. *Turk J Pediatr*. 2019;61(1):111-116.
17. Babaei AH, Inaloo S, Basiratnia M. Schimke Immuno-osseous Dysplasia: A Case Report. *Indian J Nephrol*. 2019;29(4):291-294.
18. Baradaran-Heravi A, Lange J, Asakura Y, Cochran P, Massella L, Boerkoel CF. Bone marrow transplantation in Schimke immuno-osseous dysplasia. *Am J Med Genet A*. 2013;161A(10):2609-2613.
19. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Stein TI, Nudel R, Lieder I, Mazor Y, Kaplan S, Dahary D, Warshawsky D, Guan-Golan Y, Kohn A, Rappaport N, Safran M, Lancet D. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Curr Protoc Bioinformatics*. 2016;54:1.30.1-1.30.33.
20. Zivicnjak M, Franke D, Zenker M, Hoyer J, Lücke T, Pape L, Ehrich JH. SMARCAL1 mutations: a cause of prepubertal idiopathic steroid-resistant nephrotic syndrome. *Pediatr Res*. 2009;65(5):564-8.
21. Xiong S, Shuai L, Li X, Dang X, Wu X, He Q. Podocytic infolding in Schimke immuno-osseous dysplasia with novel SMARCAL1 mutations: a case report. *BMC Nephrol*. 2020;21(1):170.
22. Dekel B, Metsuyanim S, Goldstein N, Pode-Shakked N, Kovalski Y, Cohen Y, Davidovits M, Anikster Y. Schimke immuno-osseous dysplasia: expression of SMARCAL1 in blood and kidney provides novel insight into disease phenotype. *Pediatr Res*. 2008;63(4):398-403.
23. Bertulli C, Marzollo A, Doria M, Di Cesare S, La Scola C, Mencarelli F, Pasini A, Affinita MC, Vidal E, Magini P, Dimartino P, Masetti R, Greco L, Palomba P, Conti F, Pession A. Expanding Phenotype of Schimke Immuno-Osseous Dysplasia: Congenital Anomalies of the Kidneys and of the Urinary Tract and Alteration of NK Cells. *Int J Mol Sci*. 2020;21(22):8604.
24. Zieg J, Krepelova A, Baradaran-Heravi A, Levchenko E, Guillén-Navarro E, Balascakova M, Sukova M, Seeman T, Dusek J, Simankova N, Rosik T, Skalova S, Lebl J, Boerkoel CF. Rituximab resistant evans syndrome and autoimmunity in Schimke immuno-osseous dysplasia. *Pediatr Rheumatol Online J*. 2011;9(1):27.
25. Coleman MA, Eisen JA, Mohrenweiser HW. Cloning and characterization of HARP/SMARCAL1: a prokaryotic HepA-related SNF2 helicase protein from human and mouse. *Genomics*. 2000;65(3):274-82.


26. Samanta D, Ramakrishnaiah R. Diffuse Carotid Arteriosclerosis and Stroke in a Patient With Schimke Immuno-osseous Dysplasia. *Pediatr Neurol.* 2017;71:82-83.
27. Morimoto M, Kérourédan O, Gendronneau M, Shuen C, Baradaran-Heravi A, Asakura Y, Basiratnia M, Bogdanovic R, Bonneau D, Buck A, Charrow J, Cochat P, Dehaai KA, Fenççi MS, Frange P, Fründ S, Fryssira H, Keller K, Kirmani S, Kobelka C, Kohler K, Lewis DB, Massella L, McLeod DR, Milford DV, Nobili F, Olney AH, Semerci CN, Stajic N, Stein A, Taque S, Zonana J, Lücke T, Hendson G, Bonnaure-Mallet M, Boerkoel CF. Dental abnormalities in Schimke immuno-osseous dysplasia. *J Dent Res.* 2012;91(7 Suppl):29S-37S.
28. Finsen SH, Tepel M, Neland M, Rittig S, Thiesson HC. Successful low-dose immunotherapy after kidney transplantation in a 10-year-old girl with Schimke immuno-osseous dysplasia. *Pediatr Transplant.* 2023;27(5):e14495.
29. Orozco RAP, Padilla-Guzmán A, Forero-Delgadillo JM, Jiménez VAO, Pachajoa H, Parra NJV, Restrepo JM. Schimke immuno-osseous dysplasia. A case report in Colombia. *Mol Genet Metab Rep.* 2023;37:100995.
30. Malhotra R, Sharma M, Dwivedi A, Kalra S. A Case of Schimke Immunoosseous Dysplasia Caused by Large Deletion of SMARCAL1 Gene. *Indian J Endocrinol Metab.* 2021;25(4):358-360.
31. Prato G, De Grandis E, Mancardi MM, Cordani R, Giacomini T, Pisciotta L, Uccella S, Severino M, Tortora D, Pavanello M, Bertamino M, Verrina E, Caridi G, Di Rocco M, Nobili L. Schimke immuno-osseous dysplasia: two new cases with peculiar EEG pattern. *Brain Dev.* 2020;42(5):408-413.
32. Jin J, Wu K, Liu Z, Chen X, Jiang S, Wang Z, Li W. Whole Exome Sequencing Identified a Novel Biallelic SMARCAL1 Mutation in the Extremely Rare Disease SIOD. *Front Genet.* 2019;10:565.
33. Power BD, Walsh KP, Awan A, Waldron M, O'Grady MJ. Klippel-Feil syndrome as a novel feature of Schimke immunoosseous dysplasia. *Am J Med Genet A.* 2019;179(5):862-863.
34. Haffner DN, Rollins NK, Dowling MM. Reversible Cerebral Vasoconstriction Syndrome: A Novel Mechanism for Neurological Complications in Schimke Immuno-osseous Dysplasia. *Pediatr Neurol.* 2019;92:67-70.
35. Carroll C, Badu-Nkansah A, Hunley T, Baradaran-Heravi A, Cortez D, Frangoul H. Schimke Immunoosseous Dysplasia associated with undifferentiated carcinoma and a novel SMARCAL1 mutation in a child. *Pediatr Blood Cancer.* 2013;60(9):E88-90.
36. Carroll C, Hunley TE, Guo Y, Cortez D. A novel splice site mutation in SMARCAL1 results in aberrant exon definition in a child with Schimke immunoosseous dysplasia. *Am J Med Genet A.* 2015;167A(10):2260-4.
37. Sauerstein K, Schroth M, Amann K, Hoyer J, Singer H, Rauch A, Dötsch J. Pulmonary embolism--a rare complication of Schimke immunoosseous dysplasia. *Eur J Pediatr.* 2007;166(12):1285-8.
38. Clewing JM, Fryssira H, Goodman D, Smithson SF, Sloan EA, Lou S, Huang Y, Choi K, Lücke T, Alpay H, André JL, Asakura Y, Bjebyuck-Gouge N, Bogdanovic R, Bonneau D, Cancrini C, Cochat P, Cockfield S, Collard L, Cordeiro I, Cormier-Daire V, Cransberg K, Cutka K, Deschenes G, Ehrich JH, Fründ S, Georgaki H, Guillen-Navarro E, Hinkelmann B, Kanariou M, Kasap B, Kilic SS, Lama G, Lamfers P, Loirat C, Majore S, Milford D, Morin D, Ozdemir N, Pontz BF, Proesmans W, Psoni S, Reichenbach H, Reif S, Rusu C, Saraiva JM, Sakallioglu O, Schmidt B, Shoemaker L, Sigaudy S, Smith G, Sotsiou F, Stajic N, Stein A, Stray-Pedersen A, Taha D, Taque S, Tizard J, Tsimaratos M, Wong NA, Boerkoel CF. Schimke immunoosseous dysplasia: suggestions of genetic diversity. *Hum Mutat.* 2007;28(3):273-83.
39. Bökenkamp A, deJong M, van Wijk JA, Block D, van Hagen JM, Ludwig M. R561C missense mutation in the SMARCAL1 gene associated with mild Schimke immuno-osseous dysplasia. *Pediatr Nephrol.* 2005;20(12):1724-8.
40. Mobeireek A, Saleemi S, Khalid M, Imtiaz F, Almutairy EA. Tracheobronchial anomalies in a patient with Schimke immuno-osseous dysplasia (SIOD). *Am J Med Genet A.* 2015;167A(2):434-7.
41. Simon AJ, Lev A, Jeison M, Borochowitz ZU, Korn D, Lerenthal Y, Somech R. Novel SMARCAL1 bi-allelic mutations associated with a chromosomal breakage phenotype in a severe SIOD patient. *J Clin Immunol.* 2014;34(1):76-83.

42. Basiratnia M, Baradaran-Heravi A, Yavarian M, Geramizadeh B, Karimi M. Non-hodgkin lymphoma in a child with schimke immuno-osseous dysplasia. *Iran J Med Sci.* 2011;36(3):222-5.
43. Hara-Isono K, Matsubara K, Hamada R, Shimada S, Yamaguchi T, Wakui K, Miyazaki O, Muroya K, Kurosawa K, Fukami M, Ogata T, Kosho T, Kagami M. A patient with Silver-Russell syndrome with multilocus imprinting disturbance, and Schimke immuno-osseous dysplasia unmasked by uniparental isodisomy of chromosome 2. *J Hum Genet.* 2021;66(11):1121-1126.
44. Lou S, Lamfers P, McGuire N, Boerkoel CF. Longevity in Schimke immuno-osseous dysplasia. *J Med Genet.* 2002;39(12):922-5.


UNCORRECTED PROOF




**Fig. 1.** The timeline of the patient’s medical history and diagnostic procedures, and results




**Fig. 2.** **a)** Hand radiograph at 7 months of age reveals osteopenia and cupping of distal ulna (a.1). By the age of 19 months, complete resolution of rickets findings and osteopenia, and, bone age is consistent with that of a 2-year-old (a.2). At the age of 32 months, bone age is 3-year-old (a.3). **b)** Facial pictures display various dysmorphic features including; fine and sparse hair, microcephaly, prominent forehead, synophrisis, upslanting palpebral fissures, malar hypoplasia, depressed nasal bridge, bulbous nasal tip, long philtrum, thin upper lip, retrognathia, everted lower lip, posterior rotated and low set, anteverted ears, short neck. **c)** Spinal radiographs shows mild ovoid vertebra (c.1) with mild lumbar scoliosis (c.3) at the age 33 months, and, mild platyspondyly at the age of five-and-half-years. **d)** At the age of five-and-half-years, long leg radiographs demonstrate mild coxa valga deformity with metaphyseal widening of long bones, resembling an Erlenmeyer flask deformity, metaphyseal sclerosis (arrow) and osteopenia (d.1), shallow acetabular fossae and lateral displacement of capital femoral epiphysis (Arrowhead) (d.2), which is more pronounce compared to the finding at 33 months of age (c.3). There is no obvious epiphysial involvement. **e)** Cranial radiographs show J-shaped Sella turcica



**Fig. 3.** **a)** Integrative Genomics Viewer (IGV) visualization of novel homozygous c.2422\_2427+9delinsA (NM\_001127207) variant in the *SMARCA1* gene detected in the patient; **b, c)** Her parents were heterozygous for this variant



**Fig. 4.** Schematic representation of *SMARCAL1* gene structure and its protein with the reported variants. The novel variant in the patient is indicated in bold. SMARCAL1 protein has 4 domains: HepA-related protein 1 (HARP1), HARP2, helicase ATP-binding and helicase C-terminal



**Table 1.** A comprehensive overview of all reported findings with *SMARCAL1* variant in the literature along with the details of our case.

**Table 1.** A comprehensive overview of all reported findings with *SMARCAL1* variant in the literature along with the details of our case

	Patients in literature	Present Case	Reference
Sex	71 M/54 F	F	
Age (year)	9.3 mean	5.5	
<b>GROWTH &amp; ENDOCRINE FEATURES</b>			
Short stature, disproportionate	55/55 (100%)	+	1, 4, 6-18, 21-24, 26-41
Intrauterine growth retardation	68/72 (94.4%)	+	1, 4, 6-14, 17, 18, 21-24, 27, 30, 32, 37-39, 41, 43, 44
Elevated thyroid stimulating hormone (TSH)	31/61 (50.8%)	+	1, 4, 8, 13, 14, 21, 23, 24, 31-33, 42

<b>HEAD &amp; NECK</b>			
Short neck	20/22 (90.9%)	+	6, 8-10, 12, 13, 15, 17, 22, 23, 29, 30, 32, 33, 37, 39, 42, 44
Corneal opacities	4/9 (44.4%)	-	23, 24, 32
Depressed nasal bridge	48/55 (87.2%)	+	1, 5, 6, 8, 9, 11, 14, 15, 21, 24, 30, 32, 37, 38, 40, 44
Bulbous nasal tip	48/55 (87.2%)	+	5, 6, 8, 11, 13, 15, 21, 24, 30-32, 37, 38, 40, 44
Dental anomalies (including microdontia)	13/19 (68.4%)	+	8, 12, 13, 24, 29, 31, 32, 38, 44
Hyperpigmented macules	46/55 (83.6%)	+	5, 6, 9-13, 15, 16, 22-24, 30-32, 38, 40, 44
Fine hair	7/9 (77.7%)	+	1, 15, 30-32, 40
<b>ABDOMEN</b>			
Protruding abdomen	16/18 (88.8%)	+	6, 8, 9, 13, 15, 21-24, 30, 32, 38, 39, 42, 44
<b>RENAL</b>			
Nephrotic syndrome	81/83 (97.5%)	+	1, 5, 7-18, 20-24, 26-31, 33, 35-39, 42, 44
Focal segmental glomerulosclerosis	55/65 (84.6%)	N/A	1, 4, 8-12, 14, 16-18, 21, 22, 24, 28, 29, 33, 35-39, 44
Perihilar mesangial deposition of proteinaceous material	2/2 (100%)	N/A	24, 29
Renal failure	39/49 (79.5%)	+	9-14, 16-18, 20, 23, 24, 26, 27, 31, 33-35, 37, 38, 40, 43
Hypertension	23/28 (82.1%)	+	9-15, 18, 24, 26-29, 33, 38, 40, 42, 44
Proteinuria	84/84 (100%)	+	1, 4-18, 20-24, 26-39, 42, 44
<b>SKELETAL</b>			
Spondyloepiphyseal dysplasia	52/55 (94.5%)	-	5, 11, 12, 16, 18, 21, 22, 26, 29, 30-32, 35-39, 41-44
Osteopenia	6/8 (75%)	+	8, 11, 13, 17, 42
Lumbar lordosis	6/7 (85.7)	-	12, 17, 21, 24, 37
Platyspondyly	15/20 (75%)	+	6, 11-13, 17, 21, 23, 24, 29, 30, 32, 42, 43
Ovoid vertebral bodies	4/8 (50%)	+	6, 11, 29, 30
Thoracic kyphosis	3/6 (50%)	-	9, 22, 39
Short, broad iliac bones	3/3 (100%)	-	1, 21, 43

Slanted acetabular roofs/ Shallow acetabular fossae/Small capital femoral epiphyses/ Laterally displaced femoral heads/ Hip dysplasia	28/30 (93.3%)	+	9, 11-14, 17, 20-24, 26, 27, 29-32, 35, 38, 42-44
<b>NEUROLOGIC</b>			
Normal intelligence	15/19 (78.9%)	+	1, 6, 7, 9, 10, 12, 13, 18, 32, 38, 39, 43, 44
Motor delay	18/50 (36%)	-	4, 8, 15, 18, 23, 31, 41
Transient ischemic attacks	20/33 (60.6%)	-	10-14, 17, 18, 24, 27, 28, 31, 34, 38, 44
Moyamoya	4/11 (36.3%)	-	11, 12, 14, 17
Cerebral infarcts	44/94 (46.8%)	-	4, 5, 9-11, 17, 18, 23, 24, 26, 29, 33, 34, 38, 44
<b>HEMATOLOGY</b>			
Neutropenia	27/51 (52.9%)	-	5, 6, 11, 15, 16, 18, 23, 24, 35, 38, 40, 44
Lymphopenia	69/79 (87.3%)	+	1, 5, 6, 9-12, 15-18, 23, 24, 28, 32, 35, 37-41, 44
Thrombocytopenia	19/46 (41.3%)	+	5, 9, 11, 15, 17, 18, 24, 38, 40
Anemia	22/45 (48.8%)	+	5, 9-12, 15-18, 24, 37, 38, 44
<b>IMMUNOLOGY</b>			
Recurrent infections	65/104 (62.5%)	+	4-6, 9-12, 14-18, 20, 23, 24, 29, 33, 36, 38, 40, 41, 44
Defective cellular immunity	8/8 (100%)	+	6, 7, 15, 23, 24, 29
T-cell deficiency	31/31 (100%)	+	1, 6-9, 12, 15, 17, 18, 22-24, 26, 28, 29, 31-33, 35, 36, 38, 39, 41, 42
Decreased CD4+ and CD3+/CD4+ lymphocytes	24/24 (100%)	+	6-9, 12, 15-17, 22, 24, 28, 29, 35, 36, 38, 39, 41, 42
Abnormal immunoglobulin levels	7/12 (58.3)	+	22, 23, 29, 32, 38, 41
<b>ADDITIONAL FINDINGS</b>			
Fused/crossed ectopic kidney	2/125 (1.6%)	+	18, 22
Hypercalcemia	0/125 (0%)	+	
Hypophosphatemia	0/125 (0%)	+	
Elevated FSH levels	0/125 (0%)	+	